Amplia Therapeutics (ASX:ATX) enrolled 53 patients with pancreatic cancer for its ACCENT Phase 2a clinical trial, completing recruitment two months ahead of schedule, according to a Friday Australian bourse filing.
The two-stage trial explores the use of Amplia's focal adhesion kinase inhibitor narmafotinib in combination with chemotherapy in first-line patients with advanced pancreatic cancer.
The first stage of the trial identified a safe and tolerated daily oral dose of narmafotinib. It was completed in November 2023.
The second stage will explore the efficacy of the safe dose of narmafotinib. Preliminary safety, tolerability, and efficacy data were earlier reported for the initial 26 patients.
It reported a 38.5% objective response rate from the second stage, exceeding historical benchmarks. It also reported a median trial duration of 197 days for the first 26 patient groups, indicating a 68% improvement over historical data of 117 days.
The total number of patients remaining in the study is 35.
The firm's shares rose over 7% on market close on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。